{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:28:43Z","timestamp":1792895323884,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,28]],"date-time":"2027-05-28T00:00:00Z","timestamp":1811462400000},"content-version":"am","delay-in-days":269,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000090","name":"US Office of Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-20-1-0843"],"award-info":[{"award-number":["W81XWH-20-1-0843"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5P30CA006973-52"],"award-info":[{"award-number":["5P30CA006973-52"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["W81XWH-20-1-0843"],"award-info":[{"award-number":["W81XWH-20-1-0843"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["W81XWH-22-1-0377"],"award-info":[{"award-number":["W81XWH-22-1-0377"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.humpath.2026.106154","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:47:23Z","timestamp":1779173243000},"page":"106154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Association of genomic driver mutation, histologic subtype, and mTORC1 biomarker expression in mTOR pathway-altered renal tumors"],"prefix":"10.1016","volume":"175","author":[{"given":"Swati","family":"Bhardwaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianna","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwademilade","family":"Dairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristyna","family":"Pivovarcikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean R.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Antic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedram","family":"Argani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushal","family":"Asrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0494-9067","authenticated-orcid":false,"given":"Tamara L.","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.humpath.2026.106154_bib1","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.humpath.2026.106154_bib2","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.humpath.2026.106154_bib3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1152\/physiol.00026.2024","article-title":"The spectrum of renal \u201cTFEopathies\u201d: flipping the mTOR switch in renal tumorigenesis","volume":"39","author":"Alesi","year":"2024","journal-title":"Physiology"},{"issue":"11","key":"10.1016\/j.humpath.2026.106154_bib4","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.tcb.2022.04.012","article-title":"Non-canonical mTORC1 signaling at the lysosome","volume":"32","author":"Napolitano","year":"2022","journal-title":"Trends Cell Biol"},{"issue":"2","key":"10.1016\/j.humpath.2026.106154_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/PAP.0000000000000419","article-title":"Renal cell carcinoma associated with TSC\/MTOR genomic alterations: an update on its expanding spectrum and an approach to clinicopathologic Work-up","volume":"31","author":"Shah","year":"2024","journal-title":"Adv Anat Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2026.106154_bib6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41379-021-00971-y","article-title":"Renal cell carcinoma associated with Tuberous sclerosis complex (TSC)\/Mammalian target of rapamycin (MTOR) genetic alterations","volume":"35","author":"Argani","year":"2022","journal-title":"Mod Pathol"},{"issue":"16","key":"10.1016\/j.humpath.2026.106154_bib7","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.3390\/cancers15164043","article-title":"Recent advances in renal tumors with TSC\/mTOR pathway abnormalities in patients with Tuberous Sclerosis Complex and in the sporadic setting","volume":"15","author":"Kapur","year":"2023","journal-title":"Cancers"},{"issue":"16","key":"10.1016\/j.humpath.2026.106154_bib8","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/onc.2016.363","article-title":"mTORC1 and mTORC2 in cancer and the tumor microenvironment","volume":"36","author":"Kim","year":"2017","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.humpath.2026.106154_bib9","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.4049\/jimmunol.1501473","article-title":"Mechanistic target of rapamycin complex 1\/S6 kinase 1 signals influence T cell activation independently of ribosomal protein S6 phosphorylation","volume":"195","author":"Salmond","year":"2015","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.humpath.2026.106154_bib10","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.exphem.2006.05.002","article-title":"Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients","volume":"34","author":"Chow","year":"2006","journal-title":"Exp Hematol"},{"issue":"12","key":"10.1016\/j.humpath.2026.106154_bib11","article-title":"The preanalytic impact of simulated ischemia on PI3K biomarkers","volume":"8","author":"Ostrom","year":"2009","journal-title":"Mol Cancer Therapeut"},{"issue":"2","key":"10.1016\/j.humpath.2026.106154_bib12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/path.5875","article-title":"GPNMB expression identifies TSC1\/2\/mTOR-associated and MiT family translocation-driven renal neoplasms","volume":"257","author":"Salles","year":"2022","journal-title":"J Pathol"},{"key":"10.1016\/j.humpath.2026.106154_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2025.105799","article-title":"Unlocking diagnostic potential: a retrospective analysis of GPNMB immunohistochemistry in nearly 1000 surgical pathology specimens","volume":"159","author":"Li","year":"2025","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2026.106154_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2025.105797","article-title":"Evaluation of 3,606 renal cell tumors for TFE3 rearrangements and TFEB alterations via fluorescence in situ hybridization, next generation sequencing, and GPNMB immunohistochemistry","volume":"159","author":"Whaley","year":"2025","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2026.106154_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100426","article-title":"Glycoprotein nonmetastatic melanoma protein B (GPNMB) immunohistochemistry can be a useful ancillary tool to identify perivascular epithelioid cell tumor","volume":"37","author":"Wangsiricharoen","year":"2024","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.humpath.2026.106154_bib16","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1158\/1541-7786.MCR-18-1235","article-title":"TFE3 Xp11.2 translocation renal cell carcinoma mouse model reveals novel therapeutic targets and identifies GPNMB as a diagnostic marker for human disease","volume":"17","author":"Baba","year":"2019","journal-title":"Mol Cancer Res"},{"issue":"12","key":"10.1016\/j.humpath.2026.106154_bib17","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1172\/JCI128287","article-title":"mTORC1 feedback to AKT modulates lysosomal biogenesis through MiT\/TFE regulation","volume":"129","author":"Asrani","year":"2019","journal-title":"J Clin Investig"},{"issue":"9","key":"10.1016\/j.humpath.2026.106154_bib18","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1097\/PAS.0000000000001111","article-title":"Eosinophilic solid and cystic (ESC) renal cell carcinomas harbor TSC mutations: molecular analysis supports an expanding clinicopathologic spectrum","volume":"42","author":"Palsgrove","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2026.106154_bib19","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41379-021-00816-8","article-title":"TSC loss is a clonal event in eosinophilic solid and cystic renal cell carcinoma: a multiregional tumor sampling study","volume":"35","author":"Munari","year":"2022","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2026.106154_bib20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41379-021-00923-6","article-title":"Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC\/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases","volume":"35","author":"Farcas","year":"2022","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2026.106154_bib21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41379-021-00969-6","article-title":"Oncocytic renal neoplasms with diffuse keratin 7 immunohistochemistry harbor frequent alterations in the Mammalian target of rapamycin pathway","volume":"35","author":"Mohanty","year":"2022","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.humpath.2026.106154_bib22","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1097\/PAS.0000000000001940","article-title":"Xanthomatous giant cell renal cell carcinoma: another morphologic form of TSC -associated renal cell carcinoma","volume":"46","author":"Argani","year":"2022","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.humpath.2026.106154_bib23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/his.14816","article-title":"Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity","volume":"82","author":"Williamson","year":"2023","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2026.106154_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2024.105693","article-title":"Genetic validation of a TSC2 immunohistochemistry assay in TSC\/mTOR-pathway altered renal tumors","volume":"154","author":"Akbari","year":"2024","journal-title":"Hum Pathol"},{"issue":"7","key":"10.1016\/j.humpath.2026.106154_bib25","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/PAS.0000000000001067","article-title":"Are sporadic eosinophilic solid and cystic renal cell carcinomas characterized by somatic tuberous sclerosis gene mutations?","volume":"42","author":"Parilla","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.humpath.2026.106154_bib26","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/PAS.0000000000001457","article-title":"Eosinophilic renal cell tumors with a TSC and MTOR gene mutations are morphologically and immunohistochemically heterogenous: clinicopathologic and molecular study","volume":"44","author":"Tjota","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2026.106154_bib27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41379-021-00896-6","article-title":"Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney","volume":"35","author":"Kapur","year":"2022","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2026.106154_bib28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s41379-021-00906-7","article-title":"Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1","volume":"35","author":"Morini","year":"2022","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.humpath.2026.106154_bib29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00428-023-03673-9","article-title":"Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT","volume":"483","author":"Ricci","year":"2023","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2026.106154_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2023.1610852","article-title":"Low-grade oncocytic tumour (LOT) of the kidney is characterised by GATA3 positivity, FOXI1 negativity and mTOR pathway mutations","volume":"29","author":"Chen","year":"2023","journal-title":"Pathol Oncol Res"},{"issue":"5","key":"10.1016\/j.humpath.2026.106154_bib31","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00428-022-03283-x","article-title":"Low-grade oncocytic tumor of kidney harboring TSC\/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity","volume":"480","author":"Zhang","year":"2022","journal-title":"Virchows Arch"},{"issue":"11","key":"10.1016\/j.humpath.2026.106154_bib32","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1097\/PAS.0000000000001955","article-title":"TSC\/MTOR -associated eosinophilic renal tumors exhibit a heterogeneous clinicopathologic spectrum : a targeted next-generation sequencing and gene expression profiling study","volume":"46","author":"Xia","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2026.106154_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2021.06.002","article-title":"Co-existence of ESC-RCC, EVT, and LOT as synchronous and metachronous tumors in six patients with multifocal neoplasia but without clinical features of Tuberous sclerosis complex","volume":"116","author":"Lerma","year":"2021","journal-title":"Hum Pathol"},{"issue":"10","key":"10.1016\/j.humpath.2026.106154_bib34","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1097\/PAS.0000000000000838","article-title":"Eosinophilic solid and cystic renal cell carcinoma (ESC RCC): further morphologic and molecular characterization of ESC RCC as a distinct entity","volume":"41","author":"Trpkov","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2026.106154_bib35","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2018.06.007","article-title":"Somatic Bi-allelic loss of TSC genes in eosinophilic solid and cystic renal cell carcinoma","volume":"74","author":"Mehra","year":"2018","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.humpath.2026.106154_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13000-023-01341-9","article-title":"Eosinophilic solid and cystic renal cell carcinoma with TSC2 mutation: a case report and literature review","volume":"18","author":"He","year":"2023","journal-title":"Diagn Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2026.106154_bib37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/his.14663","article-title":"Eosinophilic solid and cystic renal cell carcinoma and renal cell carcinomas with TFEB alterations: a comparative study","volume":"81","author":"Lobo","year":"2022","journal-title":"Histopathology"},{"issue":"7","key":"10.1016\/j.humpath.2026.106154_bib38","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1177\/10668969241228295","article-title":"Recurrent MTOR mutations in renal cell carcinoma with fibromyomatous stroma: a report of 2 tumors","volume":"32","author":"Palathingal","year":"2024","journal-title":"Int J Surg Pathol"},{"issue":"8","key":"10.1016\/j.humpath.2026.106154_bib39","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/PAS.0000000000001255","article-title":"Genetic underpinnings of renal cell carcinoma with leiomyomatous stroma","volume":"43","author":"Parilla","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.humpath.2026.106154_bib40","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/PAS.0000000000001422","article-title":"\"Renal Cell Carcinoma With Leiomyomatous Stroma\" harbor somatic mutations of TSC1, TSC2, MTOR, And\/Or ELOC (TCEB1): clinicopathologic and molecular characterization of 18 sporadic tumors supports a distinct entity","volume":"44","author":"Shah","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2026.106154_bib41","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13000-022-01213-8","article-title":"Primary hemangioblastoma of the kidney with molecular analyses by next generation sequencing: a case report and review of the literature","volume":"17","author":"Wang","year":"2022","journal-title":"Diagn Pathol"},{"issue":"7","key":"10.1016\/j.humpath.2026.106154_bib42","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/PAS.0000000000002211","article-title":"Recurrent tuberous sclerosis complex\/mammalian target of rapamycin mutations define primary renal hemangioblastoma as a unique entity distinct from its central nervous system counterpart","volume":"48","author":"Wang","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2026.106154_bib43","author":"Tao","year":"2025","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2026.106154_bib44","article-title":"Renal hemangioblastoma and renal cell carcinoma with fibromyomatous stroma and hemangioblastoma-like areas belong to the spectrum of one entity","author":"Trpkov","year":"2025","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2026.106154_bib45","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-025-04362-5","article-title":"Recurrent mTOR pathway alterations in renal cell carcinoma with hemangioblastoma-like features: a multi-institutional study of 9 cases with expanding morphologic spectrum","author":"Zhao","year":"2025","journal-title":"Virchows Arch"},{"issue":"41","key":"10.1016\/j.humpath.2026.106154_bib46","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1038\/s41388-022-02443-2","article-title":"GPNMB: a potent inducer of immunosuppression in cancer","volume":"41","author":"Lazaratos","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2026.106154_bib47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.steroids.2017.10.013","article-title":"Glycoprotein non-metastatic melanoma protein B (GPNMB) and cancer: a novel potential therapeutic target","volume":"133","author":"Taya","year":"2018","journal-title":"Steroids"},{"key":"10.1016\/j.humpath.2026.106154_bib48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pharmthera.2017.05.010","article-title":"Targeting GPNMB with glembatumumab vedotin: current developments and future opportunities for the treatment of cancer","volume":"179","author":"Rose","year":"2017","journal-title":"Pharmacology & therapeutics"},{"issue":"1","key":"10.1016\/j.humpath.2026.106154_bib49","article-title":"Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer","volume":"11","author":"Huang","year":"2021","journal-title":"Sci Rep"},{"issue":"36","key":"10.1016\/j.humpath.2026.106154_bib50","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2503081122","article-title":"Tumor-expressed GPNMB orchestrates Siglec-9(+) TAM polarization and EMT to promote metastasis in triple-negative breast cancer","volume":"122","author":"Dang Cao","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"10.1016\/j.humpath.2026.106154_bib51","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1038\/s44319-025-00501-w","article-title":"GPNMB marks a quiescent cell population in melanoma and promotes metastasis formation","volume":"26","author":"Lotti","year":"2025","journal-title":"EMBO Rep"},{"issue":"3","key":"10.1016\/j.humpath.2026.106154_bib52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CMR.0000000000001019","article-title":"Patterns of expression and prognostic implication of glycoprotein nonmetastatic protein B (GPNMB) expression in sentinel lymph nodes of melanoma patients","volume":"35","author":"Beitner","year":"2025","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.humpath.2026.106154_bib53","doi-asserted-by":"crossref","first-page":"6808","DOI":"10.1038\/s41467-022-34617-7","article-title":"An mTORC1-mediated negative feedback loop constrains amino acid-induced FLCN-Rag activation in renal cells with TSC2 loss","volume":"13","author":"Asrani","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.humpath.2026.106154_bib54","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41467-023-44229-4","article-title":"TFEB drives mTORC1 hyperactivation and kidney disease in Tuberous sclerosis complex","volume":"15","author":"Alesi","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.humpath.2026.106154_bib55","doi-asserted-by":"crossref","first-page":"8822","DOI":"10.1038\/s41467-025-63885-2","article-title":"SFPQ-TFE3 reciprocally regulates mTORC1 and induces lineage plasticity in a mouse model of renal tumorigenesis","volume":"16","author":"Asrani","year":"2025","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.humpath.2026.106154_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020322","article-title":"TSC\/mTOR pathway mutation associated eosinophilic\/oncocytic renal Neoplasms: a Heterogeneous group of tumors with distinct morphology, immunohistochemical profile, and similar genetic background","volume":"10","author":"Pivovarcikova","year":"2022","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.humpath.2026.106154_bib57","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.176743","article-title":"Molecular underpinnings of dedifferentiation and aggressiveness in chromophobe renal cell carcinoma","volume":"9","author":"Kapur","year":"2024","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.humpath.2026.106154_bib58","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/PAS.0000000000002117","article-title":"Positive GPNMB immunostaining differentiates renal cell carcinoma with fibromyomatous stroma associated with TSC1\/2\/MTOR alterations from others","volume":"47","author":"Li","year":"2023","journal-title":"Am J Surg Pathol"},{"issue":"32","key":"10.1016\/j.humpath.2026.106154_bib59","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2013.54.8115","article-title":"Phase I\/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma","volume":"32","author":"Ott","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.humpath.2026.106154_bib60","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1038\/srep05155","article-title":"Activation of Rheb, but not of mTORC1, impairs spine synapse morphogenesis in Tuberous sclerosis complex","volume":"4","author":"Yasuda","year":"2014","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.humpath.2026.106154_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70167","article-title":"Targeting mTOR kinase for cancer treatment: a comprehensive review with clinical insights","volume":"86","author":"Hossain","year":"2025","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.humpath.2026.106154_bib62","article-title":"PIK3CA mutations drive therapeutic resistance in human epidermal growth factor receptor 2-Positive breast cancer","volume":"6","author":"Rasti","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"10.1016\/j.humpath.2026.106154_bib63","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1038\/oncsis.2013.46","article-title":"Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer","volume":"2","author":"Huw","year":"2013","journal-title":"Oncogenesis"},{"issue":"4","key":"10.1016\/j.humpath.2026.106154_bib64","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/PAP.0000000000000299","article-title":"Eosinophilic vacuolated tumor of the kidney: a review of evolving concepts in this novel subtype with additional insights from a case with MTOR mutation and concomitant chromosome 1 loss","volume":"28","author":"Kapur","year":"2021","journal-title":"Adv Anat Pathol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817726001231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817726001231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T04:28:53Z","timestamp":1786076933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817726001231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":64,"alternative-id":["S0046817726001231"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2026.106154","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of genomic driver mutation, histologic subtype, and mTORC1 biomarker expression in mTOR pathway-altered renal tumors","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2026.106154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106154"}}